A Phase 2a Randomized Double-Blinded, Placebo and Active Controlled Two Cohort Two Doses Cross-Over Multi-Center Study to Assess Efficacy of a Once Daily Administration of a Phosphodiesterase 5 Inhibitor (PF-00489791) for the Treatment of Vasospasm in Primary and Secondary Raynaud’s Phenomenon

Principal Investigator(s)

C. Michael Franklin, M.D. (Sub-Investigator)

Mark Lopatin, M.D. (Sub-Investigator)

David J. Chesner, D.O. (Sub-Investigator)

Elana R. Eisner, M.D. (Sub-Investigator)

Marguerite L. McGarvey, M.D. (Sub-Investigator)

Dennis A. Jerdan, M.D. (Sub-Investigator)

Charles H. Pritchard, M.D.

Clinical Trial Categories

• Raynaud's

Contact

Sue Falbo at 215-657-9977